Comprehensive Notes on Uppers (Stimulants)

Uppers (Stimulants) — Comprehensive Notes

  • Purpose and scope

    • Stimulants are the world's most widely used psychoactive drugs (per the introduction). In the U.S., examples include cocaine, methamphetamine, cigarettes, coffee. Other stimulants include ADHD medications, diet pills, caffeine, khat, kh• etc.
    • Major categories: plant stimulants, synthetic stimulants, designer/novel stimulants, look-alikes and OTC stimulants, and bath salts (new psychoactive substances, NPS).
    • Global patterns: stimulant epidemics tend to come in waves; Asia and the Americas have unique prevalence and forms (e.g., ya ba in Southeast Asia; meth in parts of Asia and US).

  • Major classes and representative substances

    • Plant stimulants: coca leaf (cocaine), khat (cathinone/cathine), arecoline (betel nut), ephedrine (ephedra), caffeine (coffee, tea, chocolate, cola), nicotine (tobacco and products), yohimbine (yohimbe tree).
    • Synthetic stimulants: amphetamines (d- and l-forms; Adderall, Dexedrine, Dexedrine; dextroamphetamine), methamphetamine (including crystal meth, ice), MDMA and related phenethylamines (MDA, MMDA, MDE).
    • Designer/novel stimulants: methcathinone (bath salts); MDPV, 6-APB, 4-methylmethcathinone (bkac); mephedrone; 6-(2-aminopropyl)benzofuran (6-APB) and many variations. These are often Schedule I or unregulated initially and frequently shift from one chemical to another.
    • Look-alikes and OTC stimulants: products that resemble prescription stimulants or illicit drugs but are sold legally; many contained caffeine, ephedrine, phenylephrine, PPA (phenylpropanolamine) before regulation.
    • OTC stimulants: caffeine products (NoDoz, Vivarin), energy drinks, and other caffeine-containing items; some ephedra-based products were banned due to safety concerns.

  • Mechanisms of action and energy processing (core concepts)

    • Normal energy processing (internal stimulants): body releases epinephrine (E) and norepinephrine (NE) to boost physical energy and confidence; dopamine (DA) also contributes to energy and motivation. The energy system is tied to the brain’s reward/survival pathway.
    • External stimulants (drug-induced energy): external stimulants hijack the brain’s energy chemicals, causing large releases of E, NE, and DA, often with additional effects on serotonin (5-HT) and other neurotransmitters.
    • Borrowed energy vs. natural energy:
    • Normal Energy Process: ext{E}
      ightarrow ext{physical energy}, ext{NE}
      ightarrow ext{confidence/motivation}, ext{DA}
      ightarrow ext{reward}/motivation
    • Drug-Induced Energy Process: exogenous stimulants amplify these pathways; can lead to heightened arousal, focus, and wakefulness, but with a risk of depletion, crash, and withdrawal.
    • Survival pathway (reward/control): stimulants act on the brain’s reward circuitry, often overactivating the “go/drive” switch and impairing the brain’s ability to return to baseline after the high.

    - Down-regulation and tolerance: continued use of strong stimulants reduces receptor availability (e.g., DA and 5-HT receptor sites) in the nucleus accumbens and other primitive-brain regions, leading to craving and addiction. See:

    extDown−regulation:fewerreceptorsites(e.g.,DA/5−HT/NEpathways)leadtoincreasedcravingandhigherintake.ext{Down-regulation: fewer receptor sites (e.g., DA/5-HT/NE pathways) lead to increased craving and higher intake.}

    • Cocaine- and meth-related neurochemistry differ in kinetics and transporter interactions, but both disrupt normal dopaminergic signaling and energy homeostasis, contributing to cravings and withdrawal.

  • Cocaine: origin, forms, pharmacology, and effects

    • Origin and plant source: from the coca leaf, grown mainly in the Andes (Colombia, Bolivia, Peru, Ecuador); refined cocaine hydrochloride is the pharmaceutical/illicit form; cocaine paste is an intermediate product.
    • Major forms and street names:
    • Cocaine HCl (powder; water-soluble; Schedule II)
    • Freebase cocaine (early “freebasing”; smoked inhalation)
    • Crack cocaine (rock; smokable freebase; “rock” or “crack”)
    • Oxidado (basuco) and other paste forms in parts of South America; smoked as paste.
    • Pharmacology and mechanism:
    • Cocaine blocks reuptake of monoamines (DA, NE, 5-HT) at transporters, increasing synaptic levels and stimulating reward pathways; this leads to a rapid, potent euphoria and heightened energy.
    • Cocaine also acts on serotonin and acetylcholine indirectly via network effects.
    • Pharmacokinetics and metabolism:
    • Half-life: t_{1/2} ext{(cocaine)}
      oughly 30 ext{ to }90 ext{ minutes}.
    • Metabolites include ecgonine methyl ester and benzoylecgonine; with alcohol present, cocaethylene forms and has a longer half-life.
    • Acute effects and clinical consequences:
    • Cardiovascular: vasoconstriction, hypertension, tachycardia; potential for arrhythmias and myocardial ischemia; risk of stroke, especially with heavy use.
    • Central nervous system: euphoria, increased confidence, alertness; potential for paranoia/psychosis with high doses or chronic use.
    • Sexual effects: increased sexual desire; may delay ejaculation at low doses but high-dose use can lead to dysfunction with chronic use.
    • Weight loss and appetite suppression.
    • Behavioral and social effects:
    • Paranoia and aggression; cocaine-associated violence; violence can be linked to cocaethylene when combined with alcohol.
    • Polydrug use common (e.g., with alcohol, heroin) leading to synergistic toxicity.
    • Psychiatric and cognitive effects:
    • Acute drug-induced paranoia and psychosis; difficult to distinguish from primary psychotic disorders; symptoms often remit with abstinence.
    • Overdose and safety concerns:
    • Overdose can cause seizures, severe hypertension, hyperthermia; not always fatal; “caine” reactions can be intense but short.
    • In ERs, chest pain with suspected cocaine may not indicate a heart attack in all cases; monitoring is essential.
    • Neonatal effects and pregnancy:
    • Prenatal cocaine exposure linked to risks including miscarriage, placental abruption, SIDS; some growth/developmental delays in infants have been reported, though long-term outcomes vary.
    • Cocaine absorption routes and absorption characteristics:
    • Intravenous and smoking produce the fastest brain levels; nasal snorting slower; chewing leaves yields far lower brain exposure than smoking or injection.
    • Cocaine metabolism and neurochemistry:
    • Cocaine blocks reuptake, increasing extracellular DA/NE/5-HT; rapid depletion of neurotransmitters occurs via enzymatic metabolism, contributing to the crash.
    • Adverse physical effects:
    • Dental erosions, seizures, GI complications, choreoathetoid movements, and cocaine-induced psychosis.
    • Epidemiology and economics:
    • Cocaine has cycles of popular use across history (late 19th century; Roaring Twenties; crack epidemic 1980s); current patterns show persistent use and global trafficking.
    • Craving and withdrawal: post-binge crash; withdrawal symptoms include anhedonia, anergia, depression, anxiety, vivid dreams, insomnia, increased appetite, psychomotor agitation, and intense cravings.
    • Salience in social and policy contexts:
    • Cocaine epidemics recur in waves; criminal networks and drug gangs participate in supply; policy responses have included penalties shifts and enforcement changes.

  • Amphetamines and methamphetamine (meth): history, forms, chemistry, and consequences

    • Historical cycles of use
    • Cycle 1 (1930s): synthesis by Lazar Edeleanu; Methedrine and Benzedrine; medical uses and early abuse; over time diverted into nonmedical use.
    • Cycle 2 (1950s–1960s): diet pills; large-scale production of amphetamine-based weight-loss drugs (e.g., Dexedrine); widespread prescription use.
    • Cycle 3 (1990s–present): methamphetamine surge, especially with the appearance of high-purity, smokable methamphetamine (“crystal meth,” “ice”).
    • Methamphetamine today
    • Highly potent, smokable forms (dextro isomer methamphetamine) with various street names (crystal, crystal meth, ice, glass, ya ba in some regions; shabu in Japan; yaoo in some Asian markets; Captagon historically, though not identical).
    • “Ice” and related forms are particularly potent, with longer-lasting effects and higher abuse potential.
    • Manufacture and distribution
    • Labs range from small “mom-and-pop” labs to large “superlabs.” Synthesis often uses pseudoephedrine or ephedrine; shake-and-bake methods enable mobile, simple production with household items. Large-scale meth production in Mexico and Asia has shaped distribution networks.
    • Environmental hazards from labs: toxic waste, residues (acetone, red phosphorus, hydrochloric acid, benzene, lead), and abandoned lab sites requiring cleanup.
    • Pharmacology and brain effects
    • Meth causes release of catecholamines (NE, E) and dopamine by reversing transporter function and blocking metabolism, leading to prolonged elevated synaptic concentrations.
    • Long-term exposure leads to neuroadaptive changes: reduced dopamine transporters and receptor density; lower limbic gray matter volume in areas like hippocampus, cingulate gyrus, and paralimbic cortex; explains craving and relapse vulnerability.
    • Some neuroimaging shows reduced prefrontal activity during craving and increased amygdala activity; relapse risk remains elevated for extended periods after abstinence.
    • Acute effects and health risks
    • Increased energy, wakefulness, euphoria; appetite suppression; increased sexual arousal; potential for hyperactivity and paranoia; hand-eye coordination impairment.
    • Hormonal and metabolic perturbations lead to dental problems, weight loss, skin picking, and sleep disturbances.
    • Chronic consequences
    • Prolonged use causes lasting neurochemical and structural changes; potential for cognitive deficits and mood disorders; possible brain swelling and neurotoxicity; partial reversibility after prolonged abstinence (often months to years).
    • Special considerations
    • Meth’s association with increased risk-taking, sexual risk behaviors, and relationship to HIV/AIDS in some communities; higher prevalence in MSM communities in certain locales.

  • Cocaine vs. amphetamines (comparative snapshot)

    • Cocaine vs. amphetamines: Similar stimulants with overlapping effects but differences in chemistry and kinetics.
    • Differences in action and duration:
    • Cocaine: rapid-onset, shorter duration; often more intense euphoria; cocaine is plant-derived (coca leaf) whereas many amphetamines are synthetic.
    • Amphetamines (including meth): longer-lasting (roughly 4–6 hours for meth vs. 40 minutes for cocaine peak effects), more prone to longer-lasting neuropsychiatric effects; often cheaper per dose but stronger chronic neuroadaptations.
    • Addiction and cost dynamics:
    • Heavy users of cocaine vs. meth show differences in addiction trajectories; meth often leads to earlier development of dependence in some populations; price per unit can vary widely by substance and location.
    • Routes of administration:
    • Cocaine: snorted, smoked (crack/freebase), injected; meth: snorted, smoked, injected, orally; smoking meth often provides the most intense and long-lasting high.
    • Health impacts:
    • Both can cause cardiovascular toxicity and neuropsychiatric symptoms; meth tends to cause longer-lasting neuropsychiatric symptoms; cocaine also linked to neonatal effects and pregnancy complications.

  • Smokable cocaine, crack, and related issues

    • Crack/crack cocaine: smokable freebase form; faster brain delivery via lungs; often associated with a rapid onset and strong craving.
    • Freebase vs. crack: chemically similar, different preparation methods; “crack” often formed with baking soda; it allows rapid absorption and intense but brief high.
    • Pharmacology and side effects: similar to cocaine but more intense due to rapid pulmonary absorption; risks include chest pain, respiratory issues, “crack lung,” anxiety, irritability, and violence, especially with heavy or chronic use.
    • Market and social consequences: crack epidemics have had significant social impacts on inner-city communities; high levels of violence and criminal activity associated with crack distribution; crack use has often been linked to severe social and economic disruption in affected areas.

  • Designer designer stimulants and bath salts

    • Bath salts and NPS (new psychoactive substances) include compounds like MDPV and mephedrone, often sold as legal or “not for human consumption” substances.
    • Pharmacology: bath salts mimic stimulant effects via monoaminergic systems; they can dramatically alter heart rate, blood pressure, and mood; unpredictable potency and toxicology due to rapid changes in chemical composition.
    • Public health issues: rapid emergence and evolving chemistry make detection challenging; many jurisdictions struggle to regulate and test for these substances; reports of aggressive behavior, psychosis, and dangerous cardiovascular effects.

  • Caffeine and energy drinks

    • Ubiquity: caffeine is the most commonly used stimulant globally; caffeine sources include coffee, tea, chocolate, cola, energy drinks, guarana, mate, and yoco.
    • Typical caffeine content (per 8 oz serving where listed):
    • Instant coffee: 95extmg95 ext{ mg}
    • Brewed coffee: 135ext–160extmg135 ext{–}160 ext{ mg}
    • Tea (green): 15ext–30extmg15 ext{–}30 ext{ mg}; Tea (1-minute brew): 60extmg60 ext{ mg}; Black tea: 40ext–60extmg40 ext{–}60 ext{ mg}
    • Soft drinks (8–12 oz): 35ext–38extmg35 ext{–}38 ext{ mg} (Coca-Cola, Pepsi)
    • Energy drinks: typically around 80extmg80 ext{ mg} per 8 oz; some have higher amounts; Red Bull often around 80 mg per can; Monster around 80–160 mg per can depending on size
    • Chocolate: 4 oz milk chocolate ~ 32extmg32 ext{ mg}; 4 oz dark ~ 80extmg80 ext{ mg}
    • Energy shots (2 oz): around 200–300 mg total caffeine
    • Pharmacology: caffeine is a xanthine that blocks adenosine receptors, promoting wakefulness and alertness; also acts as a bronchodilator; can enhance mood and cognitive performance at moderate doses but can cause anxiety, insomnia, gastric irritation, and increased blood pressure at higher doses.
    • Health implications: dose-dependent effects; chronic high intake linked to cardiovascular strain; high caffeine intake can lead to dependence and withdrawal headaches; heavy caffeine consumption interacts with sleep and anxiety disorders; caffeine is included in many OTC stimulants and energy products.

  • Nicotine and tobacco products

    • Nicotine as the primary addictive component of tobacco; rapid CNS effects via nicotinic acetylcholine receptors; acts as a stimulant and mild relaxant.
    • Forms of tobacco and products: cigarettes, cigars, pipe tobacco, smokeless tobacco (moist snuff, snus, chewing tobacco, dissolvables), electronic cigarettes (e-cigarettes/vaping).
    • Health impacts and systemic effects: cardiovascular disease, respiratory disease, cancer risks (lung cancer, oral cancers, etc.), and broader systemic health effects.
    • Addiction and dependence: nicotine dependence develops rapidly; withdrawal includes irritability, anxiety, craving; nicotine acts on cholinergic pathways and modulates dopamine release, contributing to mood and reward.
    • Secondhand exposure: significant public health concerns; secondhand smoke linked to cardiovascular disease, lung cancer, and respiratory illnesses in non-smokers.
    • Social and regulatory context: heavy regulation of cigarette advertising; public health campaigns; soda-tax style economic and policy responses; e-cigarettes are regulated differently across regions; debates about safety and youth use.
    • Cessation strategies: pharmacotherapies such as varenicline (Chantix), bupropion (Zyban), nicotine replacement therapies (patches, gum, lozenges, nasal spray, inhalers); behavior therapy and community programs; vaccines in development; e-cigarettes as cessation aids are controversial.

  • ADHD medications and diet pills (therapeutic uses and abuse risk)

    • ADHD medications (stimulants): methylphenidate (Ritalin and generics), amphetamines (Adderall, Dexedrine), lisdexamfetamine (Vyvanse); non-stimulant options include atomoxetine (Strattera) and guanfacine (Intuniv).
    • Pharmacology: stimulants increase extracellular dopamine and norepinephrine by promoting release and blocking reuptake; theories suggest dopamine depletion in ADHD; stimulants can help focus and reduce hyperactivity in ADHD patients, and for some, improve executive function and attention.
    • Prevalence and cost: millions of prescriptions; ADHD diagnoses rise in youth and can persist into adulthood; US prescriptions in 2013 exceeded $7.2B annually (for ADHD medications).
    • Risks and concerns:
    • Misuse and diversion: adolescents and college students may misuse ADHD meds for cognitive enhancement or weight loss; some individuals obtain prescriptions and sell or share medications; nonmedical use rises in some settings.
    • Side effects and safety: psychosis or mania risks (though relatively rare when used as prescribed); potential liver toxicity with some non-stimulants; concern about long-term effects on developing brains and addiction liability for those with comorbid substance-use disorders.
    • Treatment approaches: avoiding monotherapy in some cases; combination with behavioral therapy and parent training; in some cases, stimulant treatment reduces later risk of substance abuse when used appropriately in ADHD children and adolescents.

  • Diet pills and weight-control stimulants

    • History: amphetamine and amphetamine congeners (e.g., Pondimin/fenfluramine and Redux/dexfenfluramine) used as diet pills; known cardiovascular risks; the Fen-Phen combination led to lawsuits and eventual withdrawal.
    • Notable drugs: fenfluramine (Pondimin), dexfenfluramine (Redux); pemoline (Cylert) and diethylpropion (Tenuate); sometimes combined with caffeine and ephedrine.
    • Health and regulatory outcomes: the FDA banned many OTC stimulants in the 1980s and 1990s; major lawsuits led to settlements and tighter controls on weight-loss drug promotion; long-term use often yields weight regain.

  • Bath salts and new psychoactive substances (NPS)

    • Overview: synthetic cathinones (bath salts) and related stimulants; frequently marketed as “not for human consumption”; widespread variability in potency and composition.
    • Health concerns: rapid onset of tachycardia, hypertension, agitation, paranoia; risk of violent behavior; difficult to test and regulate because composition changes quickly.

  • Energy drinks and the caffeine-health interface

    • Market and consumption: energy drinks (e.g., Red Bull, Monster) dominate the sector; often contain caffeine, taurine, sugars, B vitamins; sometimes marketed as performance boosters.
    • Risks: high caffeine and sugar loads can cause tachycardia, hypertension, anxiety, sleep disturbances; combining energy drinks with alcohol can mask impairment and increase risk-taking; regulatory action varies by country.

  • Social, economic, and ethical implications of stimulant use

    • Public health costs: mortality and morbidity from tobacco and cocaine/meth use; billions of dollars in healthcare costs and lost productivity.
    • Social consequences: crime, violence, drug markets, gang involvement, trafficking, and systemic inequalities.
    • Ethical considerations: balancing individual freedom with public health and safety; policy responses include regulation, taxation, advertising restrictions, and prevention programs.
    • Recovery and prevention: emphasis on early intervention, education on risks, and integration of medical and psychosocial supports; lifestyle factors that support health (sleep, nutrition, exercise) can reduce vulnerability to stimulant misuse.

  • Key numerical references and formulas (LaTeX formatting)

    • Cocaine pharmacokinetics:
    • Cocaine half-life: t1/2ext(cocaine)≈30ext−−90extminutest_{1/2} ext{(cocaine)} \approx 30 ext{--}90 ext{ minutes}
    • Cocaethylene half-life: t1/2(extcocaethylene)≈2exthourst_{1/2}( ext{cocaethylene}) \approx 2 ext{ hours}
    • Cocaine and tobacco context:
    • Typical blood nicotine in smokers: [extNicotine]blood≈5→40 μg/L[ ext{Nicotine} ]_{blood} \approx 5\to40\ \mu\text{g/L}
    • Lethal nicotine dose: ≈70 mg\approx 70\ \text{mg}
    • Caffeine content (typical values from the table):
    • Instant coffee: ext≈95 mgext{≈} 95\text{ mg}
    • Brewed coffee: ext≈135–160 mgext{≈} 135\text{–}160\text{ mg}
    • Tea (green): ext≈15–30 mgext{≈} 15\text{–}30\text{ mg}
    • Black tea (8 oz): 40–60 mg40\text{–}60\text{ mg}
    • Coca-Cola/Pepsi (12 oz): 35\–38\text{ mg}
    • Red Bull (8 oz): ≈80 mg≈80\text{ mg}
    • Energy shots (2 oz): up to 200\–300\text{ mg}
    • Chocolate (4 oz): Milk 32 mg;Dark 80 mgMilk ~32\,mg; Dark ~80\,mg
    • Nicotine pharmacology and smoke exposure:
    • Nicotine concentration in blood after a typical cigarette: ext 25 μg/Lext{~} 25\ \mu\text{g/L}
    • Fatal blood nicotine exposure: ≈70 mg\approx 70\ \text{mg}
    • General tobacco economics: the U.S. smoking-related deaths: about 480,000 per year due to smoking and secondhand smoke combined (HHHS reports).

  • Connections to prior topics and real-world relevance

    • The wave-like patterns of stimulant use correspond with supply-side changes, regulation, and public health campaigns.
    • ADHD treatment intersects with substance use risk, underscoring the importance of monitored pharmacotherapy and behavioral supports.
    • The social consequences of crack cocaine in the 1980s illustrate how market dynamics, pricing, and drug form influence both public health and crime.
    • The regulatory history of diet pills (fenfluramine/dexfenfluramine) demonstrates the long-term consequences of pharmacological shortcuts for weight loss and the need for rigorous safety monitoring.
    • The nicotine section ties into a broad public health narrative: tobacco as a social and economic enterprise with significant health and policy implications; cessation strategies and the ongoing regulatory evolution (e-cigarettes, flavor bans, advertising restrictions).

  • Ethical, philosophical, and practical implications

    • Individual autonomy vs societal risk: how to regulate and educate about stimulants without over-policing or stigmatizing.
    • Public health ethics: balancing harm minimization with equity; addressing addictive substances that disproportionately affect certain communities.
    • The legitimacy of medical use vs abuse risk: ADHD meds and diet pills demonstrate the tension between therapeutic benefit and potential misuse.
    • The role of industry and advertising: historical tobacco marketing to youth and the subsequent policy actions highlight the power and responsibility of industry in public health.
    • Environmental and societal costs: meth labs create environmental hazards; illegal drug production impacts communities beyond users.

  • Quick reference: major terms and definitions

    • Uppers: stimulants; broadly include cocaine, amphetamines, caffeine, nicotine, khat, betel nut, ephedra, yohimbine, MDMA, and related analogues.
    • Dopamine (DA), norepinephrine (NE), epinephrine (E): key neurotransmitters involved in energy, motivation, mood, and the reward pathway; stimulants modulate their synaptic availability.
    • Cocaethylene: active metabolite formed when cocaine combines with alcohol; has distinct pharmacokinetic and toxicological properties.
    • t_{1/2}: half-life of a drug in the body; critical for understanding duration of action and withdrawal windows.
    • NPS (new psychoactive substances): a broad category of evolving synthetic stimulants; often designed to circumvent regulation; poses testing and public health challenges.

  • Summary takeaway

    • Stimulants broadly increase energy and alertness via elevations in brain monoamines (DA, NE, E, 5-HT) but carry substantial risks including cardiovascular toxicity, psychiatric disturbances, weight loss, and addiction. The societal costs (healthcare, crime, and lost productivity) demand balanced public health strategies, including regulation, prevention, treatment, and harm-reduction approaches. The landscape of stimulants is continually evolving with new designer drugs, novel formulations, and shifting regulatory responses; staying informed about pharmacology, risks, and policy developments is essential for exam success and practical understanding.